PLACEBO PERFORMS AS WELL AS ANTIDEPRESSANT IN TREATING DEPRESSION

THIS INFORMATION FIRST CAME TO LIGHT 5 YEARS AGO BUT FEW SEEM TO HAVE BEEN MADE AWARE, SO IN CASE YOU MISSED IT THIS INFORMATION DEFINITELY BARES REPEATING AND WE NEED YOU TO SHARE IT SO THAT OTHERS BECOME AWARE. WHAT IS LEFT OUT OF THE ARTICLE BELOW ON THIS NEW STUDY BY THE NATIONAL INSTITUTES OF HEALTH IS THAT UNLIKE AN ANTIDEPRESSANTS, A PLACEBO COSTS MUCH LESS, LACKS WITHDRAWAL SYNDROME, AND HAS FEWER SIDE EFFECTS OR AFTER EFFECTS!!!

Read More

Glaxo Is Testing Paxil on 7-Year-Olds Despite Well Known Suicide Risks

It was established years ago that Paxil carries a risk of suicide in children and teens, but GlaxoSmithKline (GSK) has for the last 18 months been conducting a study of the antidepressant in kids as young as seven — in Japan. It’s not clear why the company would want to draw more attention to its already controversial pill, but it appears as if GSK might be hoping to see a reduced suicide risk in a small population of users — a result the company could use to cast doubt on the Paxil-equals-teen-suicide meme that dominates discussion of the drug.

Read More

PROZAC/SSRIs: Problematic [DEADLY!] For Bipolars: Dr. David Gratzer

Pay for the blue pill that works, not the red one that
doesn’t. That’s the president’s simple prescription for improving American
health care, one that relies on government panels and committees to set
guidelines for doctors and patients alike.

At least, that’s the
theory.

The theory met messy reality last week when the U.S. Preventive
Services Task Force recommended that women in their 40s shouldn’t get
mammograms. But the secretary of health and human services — who, incidentally,
oversees this panel — thinks women probably should. And the American Cancer
Society believes that they definitely should; major private insurance companies,

for the record, will continue to fund the tests.

Read More